The UK Patents Court upheld the validity of Wyeth’s patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein used in meningitis B vaccines, rejecting GSK’s allegations of lack of entitlement to two of the claimed priority dates, lack of novelty, obviousness (both conventional and so-called “AgrEvo” obviousness), insufficiency and added matter.  The court also held that a number of the claims were infringed by GSK’s meningitis B vaccine, Bexsero.

A full summary of this case has been published on Kluwer IP Law.

image_pdfimage_print

Leave a Reply

Your email address will not be published. Required fields are marked *